Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX19.550,14+0,03 %

Gold2.653,88+0,09 %

Öl (Brent)73,80-4,77 %

Dow Jones43.151,45+0,09 %

US Tech 10020.410,63-0,31 %

EUR/USD1,090780,00 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Alpha Cognition Aktie

Aktie

ISIN: CA02074J2048 WKN: A3CNL7 SYM: ACOG Land Flagge CA

Kanada

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,5400

CAD

+3,85 %

+0,0200 CAD

Letzter Kurs 11.10.24 CSE

Geldkurs

10:50:10

0,5100

CAD

500 STK

Briefkurs

10:50:10

0,5600

CAD

26.000 STK

Alpha Cognition Aktie kaufen

Neueste Nachrichten

Alpha Cognition Announces Change of Officer 04.10.24 · Business Wire (engl.) · Alpha Cognition
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing 24.09.24 · Business Wire (engl.) · Alpha Cognition
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL for Mild to Moderate Alzheimer’s Disease 19.08.24 · Business Wire (engl.) · Alpha Cognition
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth 13.08.24 · Business Wire (engl.) · Alpha Cognition
Alpha Cognition’s Oral Therapy ZUNVEYL Receives FDA Approval to Treat Alzheimer's Disease 29.07.24 · Business Wire (engl.) · Alpha Cognition
Alpha Cognition Announces First Quarter of 2024 Results and Provides Corporate Update 15.05.24 · Business Wire (engl.) · Alpha Cognition
Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update 04.04.24 · Business Wire (engl.) · Alpha Cognition
Alpha Cognition to Present at the Emerging Growth Conference on April 3, 2024 at 12: 00pm EDT. 20.03.24 · Business Wire (engl.) · Alpha Cognition
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease 22.02.24 · Business Wire (engl.) · Alpha Cognition
Alpha Cognition Provides Business Update 12.02.24 · Business Wire (engl.) · Alpha Cognition
Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment 19.01.24 · Business Wire (engl.) · Alpha Cognition
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering 22.12.23 · Business Wire (engl.) · Alpha Cognition

1
2

Meistgelesen

30 Tage
12 Monate

Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge ... 136 Leser
Alpha Cognition Announces Change of Officer 116 Leser

Alpha Cognition’s Oral Therapy ZUNVEYL Receives FDA Approval to Treat Alzheimer's Disease 276 Leser
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for ... 200 Leser
Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the ... 192 Leser
Alpha Cognition Announces First Quarter of 2024 Results and Provides Corporate Update 176 Leser
Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update 172 Leser
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth 168 Leser
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild ... 144 Leser
Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering 140 Leser
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge ... 136 Leser
Alpha Cognition to Present at the Emerging Growth Conference on April 3, 2024 at 12: 00pm EDT. 136 Leser